|
Keep Exchange of Science-Based Information on Off-Label Uses Open, Drugmakers Tell FDA
Biopharma companies should be allowed to provide factual, non-misleading information about their products’ uses in an open, scientific dialogue whether uses are off-label or not, drugmakers are telling the FDA.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives